Is the CYP2D6 Genotype Associated with Antipsychotic-Induced Weight Gain?

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Is the CYP2D6 Genotype Associated with Antipsychotic-Induced Weight Gain? / Jürgens, Gesche; Kaas-Hansen, Benjamin Skov; Nordentoft, Merete; Werge, Thomas; Andersen, Stig Ejdrup.

In: Journal of Personalized Medicine, Vol. 12, No. 10, 1728, 10.2022.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Jürgens, G, Kaas-Hansen, BS, Nordentoft, M, Werge, T & Andersen, SE 2022, 'Is the CYP2D6 Genotype Associated with Antipsychotic-Induced Weight Gain?', Journal of Personalized Medicine, vol. 12, no. 10, 1728. https://doi.org/10.3390/jpm12101728

APA

Jürgens, G., Kaas-Hansen, B. S., Nordentoft, M., Werge, T., & Andersen, S. E. (2022). Is the CYP2D6 Genotype Associated with Antipsychotic-Induced Weight Gain? Journal of Personalized Medicine, 12(10), [1728]. https://doi.org/10.3390/jpm12101728

Vancouver

Jürgens G, Kaas-Hansen BS, Nordentoft M, Werge T, Andersen SE. Is the CYP2D6 Genotype Associated with Antipsychotic-Induced Weight Gain? Journal of Personalized Medicine. 2022 Oct;12(10). 1728. https://doi.org/10.3390/jpm12101728

Author

Jürgens, Gesche ; Kaas-Hansen, Benjamin Skov ; Nordentoft, Merete ; Werge, Thomas ; Andersen, Stig Ejdrup. / Is the CYP2D6 Genotype Associated with Antipsychotic-Induced Weight Gain?. In: Journal of Personalized Medicine. 2022 ; Vol. 12, No. 10.

Bibtex

@article{ffd5edacd6d74158aa3b438372089957,
title = "Is the CYP2D6 Genotype Associated with Antipsychotic-Induced Weight Gain?",
abstract = "Antipsychotic-induced weight gain (AIWG) is a serious adverse effect. Studies have linked genetically-predicted CYP2D6 metabolic capacity to AIWG. The evidence, however, is ambiguous. We performed multiple regression analyses examining the association between genetic-predicted CYP2D6 metabolic capacity and AIWG. Analyses were based on previously unpublished data from an RCT investigating the clinical utility of routine genotyping of CYP2D6 and CYP2C19 in patients with schizophrenia. A total of 211 patients, corresponding to 71% of the original study population, were included. Our analyses indicated an effect of genetically predicted CYP2D6 metabolic capacity on AIWG with significant weight gain in both CYP2D6 poor metabolizers (PMs) (4.00 kg (95% CI: 0.80; 7.21)) and ultrarapid metabolizers (UMs) (6.50 kg (95% CI: 1.03; 12.0)). This finding remained stable after adjustment for covariates (PMs: 4.26 kg (0.88; 7.64), UMs: 7.26 kg (1.24; 13.3)). In addition to the CYP2D6 metabolic capacity, both baseline body mass index (−0.24 (95% CI: −0.44; −0.03)) and chlorpromazine equivalents per day (0.0041 (95% CI: 0.0005; 0.0077)) were statistically significantly associated with weight change in the adjusted analysis. Our results support that the genetically predicted CYP2D6 metabolic capacity matters for AIWG.",
author = "Gesche J{\"u}rgens and Kaas-Hansen, {Benjamin Skov} and Merete Nordentoft and Thomas Werge and Andersen, {Stig Ejdrup}",
year = "2022",
month = oct,
doi = "10.3390/jpm12101728",
language = "English",
volume = "12",
journal = "Journal of Personalized Medicine",
issn = "2075-4426",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "10",

}

RIS

TY - JOUR

T1 - Is the CYP2D6 Genotype Associated with Antipsychotic-Induced Weight Gain?

AU - Jürgens, Gesche

AU - Kaas-Hansen, Benjamin Skov

AU - Nordentoft, Merete

AU - Werge, Thomas

AU - Andersen, Stig Ejdrup

PY - 2022/10

Y1 - 2022/10

N2 - Antipsychotic-induced weight gain (AIWG) is a serious adverse effect. Studies have linked genetically-predicted CYP2D6 metabolic capacity to AIWG. The evidence, however, is ambiguous. We performed multiple regression analyses examining the association between genetic-predicted CYP2D6 metabolic capacity and AIWG. Analyses were based on previously unpublished data from an RCT investigating the clinical utility of routine genotyping of CYP2D6 and CYP2C19 in patients with schizophrenia. A total of 211 patients, corresponding to 71% of the original study population, were included. Our analyses indicated an effect of genetically predicted CYP2D6 metabolic capacity on AIWG with significant weight gain in both CYP2D6 poor metabolizers (PMs) (4.00 kg (95% CI: 0.80; 7.21)) and ultrarapid metabolizers (UMs) (6.50 kg (95% CI: 1.03; 12.0)). This finding remained stable after adjustment for covariates (PMs: 4.26 kg (0.88; 7.64), UMs: 7.26 kg (1.24; 13.3)). In addition to the CYP2D6 metabolic capacity, both baseline body mass index (−0.24 (95% CI: −0.44; −0.03)) and chlorpromazine equivalents per day (0.0041 (95% CI: 0.0005; 0.0077)) were statistically significantly associated with weight change in the adjusted analysis. Our results support that the genetically predicted CYP2D6 metabolic capacity matters for AIWG.

AB - Antipsychotic-induced weight gain (AIWG) is a serious adverse effect. Studies have linked genetically-predicted CYP2D6 metabolic capacity to AIWG. The evidence, however, is ambiguous. We performed multiple regression analyses examining the association between genetic-predicted CYP2D6 metabolic capacity and AIWG. Analyses were based on previously unpublished data from an RCT investigating the clinical utility of routine genotyping of CYP2D6 and CYP2C19 in patients with schizophrenia. A total of 211 patients, corresponding to 71% of the original study population, were included. Our analyses indicated an effect of genetically predicted CYP2D6 metabolic capacity on AIWG with significant weight gain in both CYP2D6 poor metabolizers (PMs) (4.00 kg (95% CI: 0.80; 7.21)) and ultrarapid metabolizers (UMs) (6.50 kg (95% CI: 1.03; 12.0)). This finding remained stable after adjustment for covariates (PMs: 4.26 kg (0.88; 7.64), UMs: 7.26 kg (1.24; 13.3)). In addition to the CYP2D6 metabolic capacity, both baseline body mass index (−0.24 (95% CI: −0.44; −0.03)) and chlorpromazine equivalents per day (0.0041 (95% CI: 0.0005; 0.0077)) were statistically significantly associated with weight change in the adjusted analysis. Our results support that the genetically predicted CYP2D6 metabolic capacity matters for AIWG.

U2 - 10.3390/jpm12101728

DO - 10.3390/jpm12101728

M3 - Journal article

C2 - 36294867

VL - 12

JO - Journal of Personalized Medicine

JF - Journal of Personalized Medicine

SN - 2075-4426

IS - 10

M1 - 1728

ER -

ID: 322567285